Group 1: Company Overview and Leadership - The meeting was held on March 17, 2026, in Shanghai, with key personnel including Chairman Zhang Junzheng and Vice General Manager Wang Shigang [2] - The presentation covered the development history of the company and an overview of its two main business segments [2] Group 2: PVP Product Insights - Current PVP product prices are low, but future price recovery is expected as the industry undergoes capacity clearing and consolidation [3] - The company plans to increase PVP production capacity by 15,000 tons, aiming for a total capacity of over 20,000 tons per year [3] - The current capacity utilization rate for PVP is high, aligning well with market demand [3] - The company is focusing on optimizing its product structure to increase the proportion of high-end products, which is expected to improve gross margins [3] Group 3: Raw Material and Market Conditions - The core raw material for the company's products, BDO, has remained stable with slight fluctuations since 2026, without significant price increases [3] - Rising oil prices have not yet impacted the pricing of the company's related products [3] Group 4: Investment in Biopharmaceuticals - The company has invested in five pharmaceutical-related entities, with key products under development including EAL® for liver cancer and CAR-T therapies [4][5] - Strategic cooperation is underway with Huada Biotech for the construction of a CAR-T drug production facility with an annual capacity of 8,000 to 10,000 doses [5] Group 5: Profit Distribution and Shareholder Returns - From 2022 to 2024, the company achieved a cumulative net profit of approximately 20.24 billion CNY, with cash dividends totaling about 11.34 billion CNY [5] - The cash dividend amount over the past three years accounted for approximately 89.15% of the net profit during the same period [5] - The company is committed to maintaining a high dividend payout ratio while balancing long-term development and operational funding needs [5]

Group 1 - The company holds an 11.1111% stake in New Anjin [2] - New Anjin's individualized drug injection P01 is currently advancing clinical trials as planned [2]

Group 1 - The core point of the article is the progress of clinical trials for Nuanzin's personalized drug injection P01, which is the world's first personalized tumor neoantigen peptide vaccine approved by both Chinese and American drug regulatory authorities [2][3] - New Source (300109.SZ) holds an 11.1111% stake in Nuanzin and has confirmed that the clinical trials for P01 are progressing as planned [2] - The company emphasizes its commitment to timely, fair, and significant information disclosure in compliance with legal obligations [2]